AI Generated Image
Scientists Found a Surprising Effect of Ozempic. It Involves Your Lungs
Gizmodo • • health
Key Points:
- UK researchers analyzed medical records and found that people with asthma or COPD taking GLP-1 medications like semaglutide (Ozempic) had significantly fewer respiratory flare-ups compared to those on other diabetes drugs.
- The study showed semaglutide users experienced nearly a 40% reduction in asthma attacks and a 20% reduction in COPD exacerbations, suggesting potential respiratory benefits beyond diabetes and obesity treatment.
- These findings, presented at the European Respiratory Society Congress, indicate a correlation but do not establish causation, and the study has yet to undergo peer review.
- Researchers caution against using GLP-1 drugs solely for respiratory issues without further evidence and recommend clinical trials to confirm these benefits and explore their role in managing airway diseases.
- Experts emphasize the need for trials that assess respiratory outcomes alongside metabolic health to develop personalized treatments for airway diseases linked to obesity and metabolic dysfunction.
